ETOPOSIDE
Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma
Northwestern UniversitySmall moleculePhase 3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Northwestern University | Phase 3 | BB |
PREDNISONE TABLETS National Cancer Institute (NCI) | Phase 3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 3 | BB |
FILGRASTIM National Cancer Institute (NCI) | Phase 3 | BB |
Cyclophosphamide Northwestern University | Phase 3 | BB |
View all 22 →
Same molecule, other indications
ETOPOSIDE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →